Text Size

Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00801333
First received: December 2, 2008
Last updated: May 2, 2013
Last verified: April 2013
History of Changes
  Purpose

Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.

The major goal of the project is to develop human iPS cells from various types of cell cultures or lines from existing collections. The IPS cells will be developed for modeling diseases, for developing the technology that may eventually allow the use of IPS cells for transplantation therapy, and for basic research.


Condition
Amyotrophic Lateral Sclerosis

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Estimated Enrollment: 25
Study Start Date: November 2008
Estimated Study Completion Date: December 2013
Detailed Description:

The potential to reprogram somatic cells into an embryonic state raises multiple basic research questions related both to the process of reprogramming and the properties of iPS cells. We will use various approaches to study the molecular mechanisms and processes that occur during reprogramming. We will use various experimental systems to characterize and study the properties of the iPS cells, their biology, developmental potential, capability to give rise to functional differentiated progeny etc.

We will induce the differentiation of the iPS cells towards specific cell lineages and the progeny can be used to study the pathogenesis of diseases. They will be used for developing new therapeutic approaches and for high throughput screening of factors for potential toxic or therapeutic effects.

All samples will be non-identified.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

We will use human somatic cells from existing collections.

Criteria

Inclusion Criteria:

  • Volunteers
  • Male and Female

Exclusion Criteria:

  • Below the official age of consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00801333

Locations
Israel
Hadassah Medical Organization - Ein Kerem Campus
Jerusalem, Israel, 91120
Sponsors and Collaborators
Hadassah Medical Organization
  More Information

Publications:

Responsible Party: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00801333     History of Changes
Other Study ID Numbers: 0511-08-HMO
Study First Received: December 2, 2008
Last Updated: May 2, 2013
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
ALS

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Sclerosis
Motor Neuron Disease
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
 Neurodegenerative Diseases
TDP-43 Proteinopathies
Neuromuscular Diseases
Proteostasis Deficiencies
Metabolic Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 19, 2013